Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Neoplasms × Adjuvants, Immunologic × Clear all

Phase

Status

Completed 2 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 1 Resectable Esophageal Cancer 1 Pleural Mesothelial Neoplasm 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Breast Neoplasms 1

Interventions

pembrolizumab 27 Cyclophosphamide 17 Nivolumab 16 fludarabine 8 Surveys and Questionnaires 8 Paclitaxel 8 Exercise 8 Doxorubicin 8 Carboplatin 8 Bevacizumab 8 budigalimab 7 atezolizumab 7 Radiotherapy 7 Fluorouracil 7 Docetaxel 7 Dexamethasone 7 Blood Specimen Collection 7 venetoclax 6 lenvatinib 6 cabozantinib 6 Rituximab 6 Prednisone 6 Pemetrexed 6 Oxaliplatin 6 Gemcitabine 6 fludarabine phosphate 5 durvalumab 5 avelumab 5 Vincristine 5 Leucovorin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03835520 2023-12-11

Plasma-Target

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase NA Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡